Previous 10 | Next 10 |
2024-04-01 16:55:25 ET More on Gritstone bio, Humana, etc. UnitedHealth Group: Buy The Recent Pullback - Long-Term Tailwinds Remain Excellent UnitedHealth Group: Optum To Drive Growth But Watch For Regulatory Risk Humana: This Year's Drop Might Have Created A Buying ...
2024-04-01 16:15:17 ET More on Gritstone bio Gritstone bio: Looking For Validation In 2024 Gritstone to cut 40% of staff due to funding delay, stock plunges 23% Seeking Alpha’s Quant Rating on Gritstone bio Historical earnings data for Gritstone bio ...
EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it has commenced an underwritten public offering of shares of its common stock (o...
-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control) in a high-risk group, where clinical data are m...
2024-03-28 15:00:00 ET More on the markets Where This Market Is Going (Technical Analysis) SPY: 2 Opposing Forces Wall Street Lunch: Fed Not Spooked By Recent Inflation Overbought conditions flash across all market caps: Bespoke Investment Group Energ...
2024-03-05 16:32:03 ET More on Gritstone bio Gritstone bio: Looking For Validation In 2024 Gritstone to cut 40% of staff due to funding delay, stock plunges 23% Seeking Alpha’s Quant Rating on Gritstone bio Historical earnings data for Gritstone bio ...
-- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone’s personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC) remain expected in 1Q 2024 -- -- National Cancer Institute-led Phase 1 study evaluat...
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced an approximately 40% reduction of its workforce. The move comes following the recently annou...
EMERYVILLE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences: ...
2024-02-16 16:37:46 ET Gainers: Iovance Biotherapeutics ( IOVA ) +4% . Microvision ( MVIS ) +3% . Iridium Communications ( IRDM ) +3% . Playtika Holding ( PLTK ) +2% . JetBlue Airways ( JBLU ) +2% . Losers...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024...